Research Analysts Set Expectations for SABS Q3 Earnings
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.29) per share for the quarter, down from […]
11 Aug 05:12 · The Markets Daily